Clinical Trial Update: GAMEC-II, Risk-adapted Protocol for Relapsed Germ Cell Tumours (GCT) [Phase 2]

View source ↗

Summary

Phase 2 trial update for GAMEC-II risk-adapted protocol in relapsed germ cell tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Testicular Neoplasms

Snippet

Sponsor: Queen Mary University of London | Conditions: Testicular Neoplasms | Phase 2 | Status: COMPLETED